Back to results
US 2017/0246305 A1Published application
mTORC1 INHIBITORS
AssigneeThe Regents of the University of California
InventorsKevan Shokat, Masanori Okaniwa
Life of this patent
Estimating the term…
Abstract
Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.
Claims27
A compound comprising a monovalent active site mTOR inhibitor covalently bound to a monovalent rapamycin or a monovalent rapamycin analog.
(canceled)
(canceled)
(canceled)
-18. (canceled)
-32. (canceled)
-41. (canceled)
-55. (canceled)
Dependencies are inferred from the claim text.